Skip to content

Prenatal Carrier Screening for Spinal Muscular Atrophy Among Thai Pregnant Women

Prenatal Carrier Screening for Spinal Muscular Atrophy Among Thai Pregnant Women

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04859179
Enrollment
200
Registered
2021-04-26
Start date
2021-03-10
Completion date
2022-03-31
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Muscular Atrophy

Keywords

spinal muscular atrophy, prenatal screening

Brief summary

Spinal muscular atrophy (SMA) prenatal carrier screening is recommended by American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG). However, in Thailand, there are no standard protocol for SMA prenatal carrier screening.

Detailed description

Spinal muscular atrophy (SMA) is one of the most common neuromuscular autosomal recessive disorders. The incidence is about 1:10,000 livebirths. There are 5 subgroups base on onset of symptoms and clinical severity. Type 1 is the most severe type which age of onset is 6 months old and life expectancy is less than 1-2 years. SMA carrier frequency is approximately 1/40-1/60. Molecular genetic testing to detect copies number of SMN1 gene is possible with as high as 95% detection rate. Since 2008, American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG) recommended SMA preconceptional and prenatal carrier screening in general population. In Thailand, there are no standard protocol for SMA prenatal carrier screening.

Interventions

None listed

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Maternal age \> 18 years * Singleton pregnancy * Gestational age ≤ 14 weeks

Exclusion criteria

* Refuse to participate the research trial

Design outcomes

Primary

MeasureTime frameDescription
Rate of acceptance of prenatal carrier screening for spinal muscular atrophy12 monthsRate of acceptance of prenatal carrier screening for spinal muscular atrophy among pregnant women seeking prenatal care

Secondary

MeasureTime frameDescription
Factors associated rate of acceptance of prenatal carrier screening for spinal muscular atrophy12 monthsFactors associated rate of acceptance of prenatal carrier screening for spinal muscular among pregnant women seeking prenatal care
Copies number of SMN1 and SMN2 genes in pregnant women12 monthsCopies number of SMN1 and SMN2 genes in pregnant women among individuals who accepted carrier screening
Carrier frequency among individuals who accepted carrier screening12 monthsScreen positive rate or rate of having 1 copy of SMN1 among individuals who accepted carrier screening
Pregnant women's attitudes toward spinal muscular atrophy and carrier screening12 monthsAfter genetic counseling, pregnant women's attitudes toward spinal muscular atrophy and carrier screening will be evaluated by validated questionnaire.

Countries

Thailand

Contacts

Primary ContactChayada Tangshewinsirikul
chayada.tan@mahidol.ac.th0898905444
Backup ContactTakol Chareonsirisuthigul
takol.cha@mahidol.ac.th021677066

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026